Journal of Bone and Mineral Metabolism

, Volume 24, Issue 3, pp 219–225

The sample size required for intervention studies on fracture prevention can be decreased by using a bone resorption marker in the inclusion criteria: prospective study of a subset of the Nagano Cohort, on behalf of the Adequate Treatment of Osteoporosis (A-TOP) Research Group

  • Masataka Shiraki
  • Tatsuhiko Kuroda
  • Toshitaka Nakamura
  • Masao Fukunaga
  • Takayuki Hosoi
  • Hajime Orimo
  • Kuniyoshi Makino
ORIGINAL ARTICLE
  • 114 Downloads

Abstract

In drug developments for osteoporosis, large-scale and longterm fracture prevention studies have been required. We investigated whether or not it was possible to reduce the sample size and observation period under new selection criteria for an osteoporotic fracture-prevention study. A Poisson regression model was used to identify independent risks for incident vertebral fracture in 515 postmenopausal women who had had no intervention for osteoporosis; this group was a subset of Nagano Cohort participants. The total observation period for this group was 2577 person-years, and a total of 146 new vertebral fractures were observed. Risk assessment for incident vertebral fracture among numerical covariates revealed that the following items showed significant independent risks for incident fractures; namely, baseline age (hazard ratio [HR]; 1.84; 95% confidence interval (CI), 1.44–2.35; P < 0.001), number of preexisting vertebral fractures (HR, 1.28; 95% CI, 1.17–1.40; P < 0.001), baseline lumbar bone mineral density (LBMD) (HR, 0.79; 95% CI, 0.71–0.88; P < 0.001), and urinary excretion of deoxypyridinoline (DPD) (HR, 1.18; 95% CI, 1.03–1.35; P = 0.016). Because the initial urinary excretion of DPD was found to be a risk for incident vertebral fracture, in addition to the conventional risks, we assessed whether or not the sample size or observation period could be reduced by the incorporation of the urinary excretion of DPD into the selection criteria of a fracture-prevention study. The assessment of sample size was calculated, using the log rank test, at a two-tailed significance level of 5% and with a power of 80%. When osteoporotic patients with preexisting fracture were selected (conventional criteria), the 3-year probability of vertebral fracture was estimated as 14.3% in the present population. On the other hand, the new vertebral fracture rate during 3 years in the osteoporotic patients with preexisting fracture plus high urinary DPD (HR, above 1.0); (new selection criteria) was estimated as 23.2%. When the HR between test drug and placebo was changed from 0.4 to 0.8, the required sample size for any level of HR showed a 40% reduction for the new selection criteria compared to the conventional criteria. Therefore, the addition of urinary DPD level to the selection criteria is useful to reduce sample size in an osteoporosis fracture-prevention study.

Key words

fracture intervention study osteoporosis vertebral fracture DPD 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy2001Osteoporosis prevention, diagnosis, and therapyJAMA285785795CrossRefGoogle Scholar
  2. 2.
    Silverman, SL Minshall, ME Shen, W Harper, KD Xie, S Health-Related Quality of Life Subgroup of the Multiple Outcomes of Raloxifene Evaluation Study2001The relationship of health-related quality of life to prevalent and incident vertebral fractures in postmenopausal women with osteoporosis: results from Multiple Outcomes of Raloxifene Evaluation StudyArthritis Rheum4426112619CrossRefPubMedGoogle Scholar
  3. 3.
    Oleksik, A, Lips, P, Dawson, A, Minshall, ME, Shen, W, Cooper, C, Kanis, J 2000Health-related quality of life in postmenopausal women with low BMD with or without prevalent vertebral fracturesJ Bone Miner Res1513841392PubMedGoogle Scholar
  4. 4.
    Kanis, JA, McCloskey, EV 1992Epidemiology of vertebral osteoporosisBone13S110PubMedGoogle Scholar
  5. 5.
    Center, JR, Nguyen, TV, Schneider, D, Sambrook, PN, Eisman, JA 1999Mortality after all major types of osteoporotic fracture in men and women: an observational studyLancet353878882CrossRefPubMedGoogle Scholar
  6. 6.
    Kado, DM, Browner, WS, Palermo, L, Nevitt, MC, Genant, HK, Cummings, SR 1999Vertebral fractures and mortality in older women: a prospective study. Study of Osteoporotic Fractures Research GroupArch Intern Med15912151220CrossRefPubMedGoogle Scholar
  7. 7.
    Black, DM, Cummings, SR, Karpf, DB, Cauley, JA, Thompson, DE, Nevitt, MC, Bauer, DC, Genant, HK, Haskell, WL, Marcus, R, Ott, SM, Torner, JC, Quandt, SA, Reiss, TF, Ensrud, KE 1996Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research GroupLancet34815351541PubMedGoogle Scholar
  8. 8.
    Cummings, SR, Black, DM, Thompson, DE, Applegate, WB, Barrett-Connor, E, Musliner, TA, Palermo, L, Prineas, R, Rubin, SM, Scott, JC, Vogt, T, Wallace, R, Yates, AJ, LaCroix, AZ 1998Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention TrialJAMA28020772082PubMedGoogle Scholar
  9. 9.
    Harris, ST, Watts, NB, Genant, HK, McKeever, CD, Hangartner, T, Keller, M, Chesnut, CH,3rd, Brown, J, Eriksen, EF, Hoseyni, MS, Axelrod, DW, Miller, PD 1999Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study GroupJAMA28213441352CrossRefPubMedGoogle Scholar
  10. 10.
    Reginster, J, Minne, HW, Sorensen, OH, Hooper, M, Roux, C, Brandi, ML, Lund, B, Ethgen, D, Pack, S, Roumagnac, I, Eastell, R 2000Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study GroupOsteoporosis Int118391CrossRefGoogle Scholar
  11. 11.
    Ettinger, B, Black, DM, Mitlak, BH, Knickerbocker, RK, Nickelsen, T, Genant, HK, Christiansen, C, Delmas, PD, Zanchetta, JR, Stakkestad, J, Gloer, CC, Krueger, K, Cohen, FJ, Eckert, S, Ensrud, KE, Avioli, LV, Lips, P, Cummings, SR 1999Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) InvestigatorsJAMA282637645CrossRefPubMedGoogle Scholar
  12. 12.
    Meunier, PJ, Roux, C, Seeman, E, Ortolani, S, Badurski, JE, Spector, TD, Cannata, J, Balogh, A, Lemmel, EM, Pors-Nielsen, S, Rizzoli, R, Genant, HK, Reginster, JY 2004The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosisN Engl J Med350459468CrossRefPubMedGoogle Scholar
  13. 13.
    Kushida, K Shiraki, M Nakamura, T Kishimoto, H Morii, H Yamamoto, K Kaneda, K Fukunaga, M Inoue, T Nakashima, M Orimo, H on behalf of the Alendronate/Alfacalcidol Fracture Intervention Study Group2002The efficacy of alendronate in reducing the risk for vertebral fracture in Japanese patients with osteoporosis: a randomized, double-blind, active-controlled, double-dummy trialCurr Ther Res Clin Exp63606620Google Scholar
  14. 14.
    Director, Evaluation and Licensing Division, Pharmaceutical and Medical Safety Bureau, Ministry of Health and Welfare (1998) Guidelines Concerning Methods for Clinical Evaluation of Osteoporosis Drugs (Second Draft). Notification No 1010 of the Evaluation and Licensing Division, Pharmaceutical and Food Safety Bureau, dated November 2, 1998 (in Japanese). Japanese Minister of Health and Welfare, TokyoGoogle Scholar
  15. 15.
    Siris, ES, Miller, PD, Barrett-Connor, E, Faulkner, KG, Wehren, LE, Abbott, TA, Berger, ML, Santora, AC, Sherwood, LM 2001Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk AssessmentJAMA28628152822CrossRefPubMedGoogle Scholar
  16. 16.
    Barrett-Connor, E, Siris, ES, Wehren, LE, Miller, PD, Abbott, TA, Berger, ML, Santora, AC, Sherwood, LM 2005Osteoporosis and fracture risk in women of different ethnic groupsJ Bone Miner Res20185194PubMedGoogle Scholar
  17. 17.
    Nelson, HD, Helfand, M, Woolf, SH, Allan, JD 2002Screening for postmenopausal osteoporosis: a review of the evidence for the U.S. Preventive Services Task ForceAnn Intern Med137529541PubMedGoogle Scholar
  18. 18.
    Fujiwara, S, Kasagi, F, Masunari, N, Naito, K, Suzuki, G, Fukunaga, M 2003Fracture prediction from bone mineral density in Japanese men and womenJ Bone Miner Res1815471553PubMedGoogle Scholar
  19. 19.
    Orimo, H Hayashi, Y Fukunaga, M Sone, T Fujiwara, S Shiraki, M Kushida, K Miyamoto, S Soen, S Nishimura, J Oh-hashi, Y Hosoi, T Gorai, I Tanaka, H Igai, T Kishimoto, H Osteoporosis Diagnostic Criteria Review Committee: Japanese Society for Bone and Mineral Research2001Diagnostic criteria for primary osteoporosis: year 2000 revisionJ Bone miner Metab19331337CrossRefPubMedGoogle Scholar
  20. 20.
    Shiraki, M, Shiraki, Y, Aoki, C, Hosoi, T, Inoue, S, Kaneki, M, Ouchi, Y 1997Association of bone Mineral density with apolipoprotein E phenotypeJ Bone Miner Res1214381445PubMedGoogle Scholar
  21. 21.
    Genant, HK, Jergas, M, Palermo, L, Nevitt, M, Valentin, RS, Black, D, Cummings, SR 1996Comparison of semiquantitative visual and quantitative morphometric assessment of prevalent and incident vertebral fractures in osteoporosis. The Study of Osteoporotic Fractures Research GroupJ Bone Miner Res11984996PubMedGoogle Scholar
  22. 22.
    Fukunaga, M, Nakamura, T, Shiraki, M, Kuroda, T, Ohta, H, Hosoi, T, Orimo, H 2004Absolute height reduction and percent height ratio of the vertebral body in incident fracture in Japanese womenJ Bone Miner Metab22104110CrossRefPubMedGoogle Scholar
  23. 23.
    Shoenfeld, DA 1983Sample-size formula for the proportional-hazards regression modelBiometrika39499503Google Scholar
  24. 24.
    McClung, MR, Geusens, P, Miller, PD, Zippel, H, Bensen, WG, Roux, C, Adami, S, Fogelman, I, Diamond, T, Eastell, R, Meunier, PJ, Reginster, JY 2001Effect of risedronate on the risk of hip fracture in elderly women. HIP Intervention Program Study GroupN Engl J Med344333340CrossRefPubMedGoogle Scholar
  25. 25.
    Klotzbuecher, CM, Ross, PD, Landsman, PB, Abbott, TA,3rd, Berger, M 2000Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesisJ Bone Miner Res15721739PubMedGoogle Scholar
  26. 26.
    Ross, PD, Genant, HK, Davis, JW, Miller, PD, Wasnich, RD 1993Predicting vertebral fracture incidence from prevalent fractures and bone density among non-black, osteoporotic womenOsteoporos Int3120126CrossRefPubMedGoogle Scholar
  27. 27.
    Lips, P 1997Epidemiology and predictors of fractures associated with osteoporosisAm J Med1033S11SCrossRefPubMedGoogle Scholar
  28. 28.
    Roy, DK, O'Neill, TW, Finn, JD, Lunt, M, Silman, AJ,  et al. 2003Determinants of incident vertebral fracture in men and women: results from the European Prospective Osteoporosis Study (EPOS)Osteoporos Int141926CrossRefPubMedGoogle Scholar
  29. 29.
    Garnero, P, Hausherr, E, Chapuy, MC, Marcelli, C, Grandjean, H, Muller, C, Cormier, C, Breart, G, Meunier, PJ, Delmas, PD 1996Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective StudyJ Bone Miner Res1115311538PubMedGoogle Scholar
  30. 30.
    van Daele, PL, Seibel, MJ, Burger, H, Hofman, A, Grobbee, DE, Van Leeuwen, JP, Brikenhager, JC, Pols, HA 1996Case-control analysis of bone resorption markers, disability, and hip fracture risk: the Rotterdam studyBMJ312482483PubMedGoogle Scholar
  31. 31.
    Woitge, HW, Seibel, MJ 2000Risk assessment for osteoporosis. II. Biochemical markers of bone turnover: bone resorption indicesClin Lab Med20503525viPubMedGoogle Scholar
  32. 32.
    Garnero, P, Sornay-Rendu, E, Claustrat, B, Delmas, PD 2000Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY studyJ Bone Miner Res1515261536PubMedGoogle Scholar
  33. 33.
    Delmas, PD van de Langerijt, L Watts, NB Eastell, R Genant, H Grauer, A Cahall, DL IMPACT Study Group2005Underdiagnosis of vertebral fractures is a worldwide problem: the IMPACT studyJ Bone Miner Res20557563(Epub 2004 Dec 6)PubMedGoogle Scholar

Copyright information

© Springer-Verlag Tokyo 2006

Authors and Affiliations

  • Masataka Shiraki
    • 1
  • Tatsuhiko Kuroda
    • 2
  • Toshitaka Nakamura
    • 3
  • Masao Fukunaga
    • 4
  • Takayuki Hosoi
    • 5
  • Hajime Orimo
    • 6
  • Kuniyoshi Makino
    • 7
  1. 1.Research Institute and Practice for Involutional DiseasesAzuminoJapan
  2. 2.Public Health Research FoundationTokyoJapan
  3. 3.Department of Orthopedic SurgeryUniversity of Occupational and Environmental HealthFukuokaJapan
  4. 4.Department of Nuclear MedicineKawasaki Medical SchoolOkayamaJapan
  5. 5.Department of Endocrinology and MetabolismTokyo Metropolitan Geriatric Medical CenterTokyoJapan
  6. 6.Health Science UniversityYamanashiJapan
  7. 7.Tokyo Metropolitan Research Laboratory of Public HealthTokyoJapan

Personalised recommendations